Growth in the human augmentation sector won't happen equally. Whoever redefines this market will capture the lion's share of the $1.8 billion in profits up for grabs.
- Ekso Bionics: Now the First and Only FDA-Approved Exoskeleton
- Two Important Updates on Ekso Bionics Inc. and Consolidated Water Co.
- EKSO Stock Price Prediction Shows 1,676% Profit Potential
- Why Ekso Bionics (OTCbb: EKSO) Stock Is a Long-Term Profit Machine
- My New Price Projection for Ekso Bionics (EKSO)
- "Unloved" Pick of the Week: Ekso Bionics (OTC: EKSO) Stock
One of Wall Street's cardinal sins is a "set it and forget it" mentality. What I mean by that is there's often a flurry of interest in specific stocks and then... nothing.
That's too bad because the devil, as they say, is always in the details. In that spirit, let's check in on two of our favorite recommendations today: Ekso Bionics and Consolidated Water.
Ekso Bionics Holding (OTCBB: EKSO) stock has dipped 41% in the last three months and currently trades near $1.23 per share.
But EKSO stock is a still a long-term buy. In fact, this little-known stock has a profit potential of up to 1,676% in the next five years.
Ekso Bionics Holdings Inc. (OTCbb: EKSO) stock is one of the best long-term profit plays on the market today.
In fact, our experts say EKSO stock could climb 1,648% from today's opening price within the next five years.
As part of his research process, Fitz-Gerald visited the small Richmond, Calif., company in 2014. The technology he saw was a total game-changer.
Ekso Bionics is a cutting-edge company. Last October, we reported that its share price would go up to $21.14 by 2020.
But based on what EKSO is currently doing, and what's happening in the broader market, we've grown even more bullish on the stock.
Money Morning's "unloved" pick of the week is robotic exoskeleton company Ekso Bionics Holdings Inc. (OTC: EKSO).
Ekso stock is a favorite pick of Money Morning Chief Investment Strategist Keith Fitz-Gerald. He believes Ekso Bionics stock could rise more than 13-fold over the next five years.
As a penny stock that keeps losing money, Ekso quickly fell out of favor with investors after a wildly successful IPO. Usually that's a bad sign.